Showing results (201-210 of 213) with videos related to
Sort By:
Pageof 22
Journal of the American Academy of Dermatology|February 19, 2013
Serum 25-hydroxyvitamin D concentration does not correlate with atopic dermatitis severityYvonne E Chiu, Peter L Havens, Dawn H Siegel, et al.AIDS Education and Prevention : Official Publication of the International Society for AIDS Education|April 24, 1999
HIV risk behaviors, intentions, and perceptions among Namibian youth as assessed by a theory-based questionnaireB F Stanton, A M Fitzgerald, X Li, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|April 16, 2014
Status of voluntary medical male circumcision in Kenya: findings from 2 nationally representative surveys in Kenya, 2007 and 2012Jennifer S Galbraith, Athanasius Ochieng, Samuel Mwalili, et al.Infection|July 17, 2012
Detection of herpes viruses in the cerebrospinal fluid of adults with suspected viral meningitis in MalawiL A Benjamin, M Kelly, D Cohen, et al.Physiological Reviews|January 1, 1996
Defining the roles of parathyroid hormone-related protein in normal physiologyW M Philbrick, J J Wysolmerski, S Galbraith, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 1, 1977
Severe head injuries in three countriesB Jennett, G Teasdale, S Galbraith, et al.Nature Communications|December 31, 2024
Enhancing gene transfer to renal tubules and podocytes by context-dependent selection of AAV capsidsTaisuke Furusho, Ranjan Das, Hideyuki Hakui, et al.AIDS (London, England)|January 6, 1999
Increased protected sex and abstinence among Namibian youth following a HIV risk-reduction intervention: a randomized, longitudinal studyB F Stanton, X Li, J Kahihuata, et al.British Journal of Cancer|June 2, 2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapyC R Garrett, L L Siu, A El-Khoueiry, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsD J Jonker, L S Rosen, M B Sawyer, et al.Pageof 22